Lethal pediatric tumors bearing a particular histone H3 mutation upregulate the disialoganglioside GD2, thereby making these tumors susceptible to chimeric antigen receptor T cell–based immunotherapy.
- Christopher W. Mount
- Robbie G. Majzner
- Crystal L. Mackall
